Our journey with Oviva from Seed to Series D
By Christoph Ruedig, Partner
Posted
We are thrilled to share that our portfolio company Oviva just announced its Series D round, raising €200m to expand AI-Enabled Heathcare across Europe. This is a significant milestone in Oviva’s journey to transforming care for weight-related conditions. It follows their $80m Series C in 2021 and a year of strong growth in 2025 where the company treated its millionth patient.
We originally backed co-founders Kai and Manuel in 2016 when the team was a handful of people. As an early-stage investor and specialist in healthcare and technology, the investment fit well with our thesis of how healthcare was going to be transformed by technology. Fast forward to today and Oviva is the clear European market leader in its field. They have built an industry-defining AI-first platform that personalises care at scale, have outstanding clinical results, are loved by patients, and are probably saving healthcare systems in Europe billions in future medical expenditure.
As with all start-ups, the journey wasn’t a straight line. Over the years, Oviva entered and then exited geos and product lines, pivoted strategy, and rode the Covid wave and trough. At the heart of its success are two enduring ingredients, though: mission and team.
Oviva exists to make effective care accessible to everyone who needs it. It’s a broad and bold statement of what the company set out to do. It was born out of the fact that >200 million adults live with obesity and related chronic conditions in Europe, yet access to effective, long-term treatment remains severely limited due to outdated care models, rising demand and clinician shortages. Oviva’s mission hasn’t changed since the first days of the company. It is what inspired us to co-lead the seed round 10 years ago. And it remains its north star, driving all important decisions at board and executive level.
Anybody who has built in healthcare knows about the complexity inherent in this industry, the slow pace of change, and the challenges in driving technology adoption. Not many health technology leaders have built a business spanning several countries in Europe, each with different regulatory and reimbursement regimes, clinical practices and patient preferences. It is testament to Kai and Manuel’s vision, ambition and supreme execution that they were able to deliver on Oviva’s mission and build a pan-European category leader in this industry where so many others have failed. They have assembled a world-class leadership team, which has been instrumental in successfully scaling the company across verticals and countries.
We feel fortunate to have been able to support Oviva along its exciting journey, co-leading the company’s A round, and participating in its Series B and C rounds. As with all our investments, the partnership extends well beyond capital. AlbionVC’s in-house talent and scaling platform gives companies the resources to successfully lead, hire and scale their business. We have worked closely with Oviva on a number of critical senior appointments including board chair, CPO, GTM leadership, VPs of Engineering, Product and Marketing. We have supported their AI strategy, and helped shape provider engagement.
We’re excited about Oviva’s future. The scale of the obesity challenge across Europe remains vast, but so does the opportunity to deliver better outcomes for patients and healthcare systems alike. We remain deeply committed to Oviva’s mission and excited to continue supporting Kai and his team as they continue building Europe’s most impactful healthcare technology company.
Christoph Ruedig, Partner AlbionVC
